Mollie Leoni Biography and Net Worth

Chief Medical Officer of Kura Oncology

Dr. Leoni joined Kura with more than 15 years of drug development experience, heavily focused within the orphan disease and oncology spaces. During this time, she has held positions of increasing responsibility at pharmaceutical companies both large and small. Most recently, she served as the Executive Director of Medical Science for Kyowa Kirin, serving as the clinical lead for several oncology programs including one that resulted in the successful international registration of a treatment for cutaneous T-cell lymphoma. Dr. Leoni obtained her undergraduate and medical degrees from the University of Pennsylvania, where she also trained extensively in bioethics before entering postgraduate training at Thomas Jefferson University.

What is Mollie Leoni's net worth?: The estimated net worth of Mollie Leoni is at least $2.70 million as of November 14th, 2025. Dr. Leoni owns 225,454 shares of Kura Oncology stock worth more than $2,700,939 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Leoni may own. Learn More about Mollie Leoni's net worth.
How do I contact Mollie Leoni?: The corporate mailing address for Dr. Leoni and other Kura Oncology executives is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. Kura Oncology can also be reached via phone at (858) 500-8800 and via email at [email protected]. Learn More on Mollie Leoni's contact information.
Has Mollie Leoni been buying or selling shares of Kura Oncology?: During the past quarter, Mollie Leoni has sold $173,122.30 of Kura Oncology stock. Most recently, Mollie Leoni sold 15,485 shares of the business's stock in a transaction on Friday, November 14th. The shares were sold at an average price of $11.18, for a transaction totalling $173,122.30. Following the completion of the sale, the insider now directly owns 225,454 shares of the company's stock, valued at $2,520,575.72. Learn More on Mollie Leoni's trading history.
Who are Kura Oncology's active insiders?: Kura Oncology's insider roster includes Teresa Bair (Chief Legal Officer), Thomas Doyle (SVP, Finance and Accounting), Kathleen Ford (Chief Operating Officer), Laura Johnson (Director), Mollie Leoni (Chief Medical Officer), Thomas Malley (Director), Anthony Praill (CFO), Troy Wilson (President and Chief Executive Officer), and Saiid Zarrabian (Insider). Learn More on Kura Oncology's active insiders.
Are insiders buying or selling shares of Kura Oncology?: In the last twelve months, Kura Oncology insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $410,000.00. In the last twelve months, insiders at the sold shares 16 times. They sold a total of 137,521 shares worth more than $1,308,039.69. The most recent insider tranaction occured on November, 14th when insider Teresa Brophy Bair sold 8,804 shares worth more than $98,428.72. Insiders at Kura Oncology own 6.4% of the company. Learn More about insider trades at Kura Oncology.
Information on this page was last updated on 11/14/2025.

Mollie Leoni Insider Trading History at Kura Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2025	Sell	15,485	$11.18	$173,122.30	225,454
9/29/2025	Sell	12,314	$8.94	$110,087.16	158,439
1/28/2025	Sell	4,963	$7.87	$39,058.81	88,253

Mollie Leoni Buying and Selling Activity at Kura Oncology

Kura Oncology Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $11.98

$11.90

$12.32

50 Day Range

MA: $10.37

$8.85

$12.09

2 Week Range

Now: $11.98

$5.41

$12.49

Volume

1,438,355 shs

Average Volume

1,795,837 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21